CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com

OPHTHALMOLOGY

Ophthalmology

As a part of the Viatris deal, Biocon Biologics has exercised the option to acquire Viatris’ rights to its biosimilar Aflibercept asset, (partnered with Momenta), a proposed biosimilar to Regeneron’s Eylea, which is indicated for use in multiple ophthalmological indications. Viatris has been the ‘first to file’ for a biosimilar Aflibercept in the U.S.

Aflibercept*

Filed: Filed for approval in the U.S.

Preclinical

Clinical

Filed

Approved

Launched

*Product partnered with Momenta. Post the acquisition of Viatris’ global biosimilars business, this asset will also be a part of Biocon Biologics portfolio.

Share